Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25135486 | 1.00 | DPP4 (0.40) | DPP4DPP8DPP9CTSVCTSL | |
| SCHEMBL7724507 | 1.00 | DPP4 (0.40) | DPP4DPP8DPP9CTSVCTSL | |
| SCHEMBL12142684 | 1.00 | DPP4 (0.40) | DPP4DPP8DPP9CTSVCTSL | |
| SCHEMBL30705634 | 1.00 | DPP4 (0.40) | DPP4DPP8DPP9CTSVCTSL | |
| Hydrochloric Acid SCHEMBL25310545 | 0.99 | DPP4 (0.39) | DPP4DPP8DPP9CTSVCTSL | |
| Hydrochloric Acid SCHEMBL25310550 | 0.99 | DPP4 (0.39) | DPP4DPP8DPP9CTSVCTSL | |
| Trifluoroacetic Acid SCHEMBL30489482 | 0.93 | CTSV (0.37) | DPP4DPP8DPP9CTSVCTSL | |
| SCHEMBL30557102 | 0.91 | CTSV (0.37) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL30556788 | 0.90 | CTSV (0.36) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL25076129 | 0.88 | DPP4 (0.39) | DPP4DPP8DPP9CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067379-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| EP-1730110-B1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20100104534-A1 | HYDRAZIDO-PEPTIDES AS INHIBITORS OF HCV NS3-PROTEASE | SCHERING CORPORATION | 2010-04-29 | — | — | US | disclosed |
| US-7635694-B2 | For treating hepatitis C and related disorders such as HIV, AIDS (Acquired Immune Deficiency Syndrome) | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| WO-2008118332-A2 | HYDRAZIDO-PEPTIDES AS INHIBITORS OF HCV NS3-PROTEASE | SCHERING CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
| US-7425576-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070142300-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | MERCK SHARP & DOHME LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-7205330-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
| US-7186747-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2005087731-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005085197-A1 | CYCLOBUTENEDIONE GROUPS-CONTAINING COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142300-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SERPINB1, HAVCR2, HPN | DPP4 26/4885DPP8 16/4885DPP9 25/4885 |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | HAVCR2, RNASE1, SERPINB1 | DPP4 23/4885DPP8 10/4885DPP9 18/4885 |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | PREP, PRSS1, P4HB | DPP4 73/4885DPP8 93/4885DPP9 193/4885 |
| US-20100104534-A1 | HYDRAZIDO-PEPTIDES AS INHIBITORS OF HCV NS3-PROTEASE | PREP, HPN, VIP | DPP4 5/4885DPP8 13/4885DPP9 7/4885 |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | PRSS1, PRSS3, HPN | DPP4 111/4885DPP8 68/4885DPP9 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.